MannKind Corporation 8-K Filing Details Board Election Results and Company Information (May 2026)
MannKind Corporation filed an 8-K disclosing the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. Shareholders re-elected all nine director nominees, approved executive compensation, and ratified Deloitte & Touche LLP as independent auditors, showing strong support for the company's governance and strategic direction. The company also confirmed it is not an emerging growth company and has no undisclosed corporate actions.
Director Michael A. Friedman awarded 82,781 MannKind (MNKD) restricted stock units
MannKind Corporation director Michael A. Friedman has been awarded 82,781 restricted stock units (RSUs) that vested on May 20, 2026. These RSUs represent a contingent right to receive one share of MannKind common stock each, with the actual shares to be delivered only after Friedman separates from service on the company's board of directors. This Form 4 filing indicates an acquisition through a grant, not an open-market transaction.
MannKind (MNKD) awards 82,781 restricted stock units to director
MannKind Corp. director Christine Mundkur was awarded 82,781 restricted stock units (RSU) which vested on May 20, 2026, though the shares will not be delivered until her separation from the board. This grant, along with clarification of previously misclassified deferred RSUs, was reported in a Form 4 filing. Following these transactions, Mundkur directly holds 27,675 shares of MannKind common stock.
MannKind (MNKD) director Steven Binder receives 82,781 restricted stock units
MannKind Corporation director Steven B. Binder was granted 82,781 restricted stock units (RSUs) as part of the company's equity compensation program. These RSUs vested on May 20, 2026, but the underlying shares will only be delivered upon his separation of service from MannKind's board of directors. This grant is a compensation-related award, not an open-market purchase or sale.
[Form 4] MANNKIND CORP Insider Trading Activity
MannKind Corp's President of Endocrine Business Unit, Dominic Marasco, reported acquiring 8,474 shares of common stock at $2.95 per share through the company's Market Price Stock Purchase Plan. This transaction, approved by the board on May 20, 2026, increased his direct holdings to 344,246 shares. The report details the specifics of the acquisition and Marasco's total shareholdings, including shares from an Employee Stock Purchase Plan.
Director Sabrina Kay (NASDAQ: MNKD) awarded 82,781 MannKind RSUs
MannKind Corporation director Sabrina Kay was granted 82,781 restricted stock units (RSUs) on May 20, 2026, as compensation. This award, not a purchase, reflects a contingent right to receive one share of MannKind common stock per RSU. Her total direct common stock holdings are now 107,033 shares, plus the new RSUs, with a correction made to previously misclassified deferred RSUs.
MannKind shareholders elect directors and approve proposals at annual meeting
MannKind Corporation shareholders elected all nine director nominees and approved executive compensation, along with ratifying Deloitte & Touche LLP as their independent accounting firm at the 2026 Annual Meeting. The company also recently reported a 15% year-over-year revenue increase in Q1 2026, reaching $90 million, primarily due to the FUROSCIX acquisition, despite a non-GAAP net loss of $0.02 per share. Investors are monitoring these developments to assess MannKind's financial future.
MannKind (NASDAQ: MNKD) reports 2026 annual meeting voting results
MannKind Corporation announced the results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine directors, approved the compensation of named executive officers on an advisory basis, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026. All proposals received significant stockholder support, with detailed vote counts provided for each item, including broker non-votes.
MannKind Corp stock (US5638651064): inhaled insulin specialist draws attention after recent business updates
MannKind Corp has garnered attention due to recent business and pipeline updates concerning its inhaled insulin Afrezza and its growing portfolio in pulmonary arterial hypertension. The company's strategy involves leveraging its Technosphere delivery platform for direct sales, partnerships, and pipeline expansion in chronic diseases. Investors are closely monitoring MannKind's revenue growth, execution on partnerships, and ongoing investments in R&D as it navigates competitive markets and works towards profitability.
How Revenue Jump And United Therapeutics Deal At MannKind (MNKD) Has Changed Its Investment Story
MannKind Corporation reported a 15% year-on-year revenue increase in Q1 2026, reaching US$90.2 million, driven by Furoscix sales and Tyvaso DPI royalties. This growth, coupled with an expanded United Therapeutics collaboration for Ralinepag DPI, reinforces MannKind's inhaled drug delivery platform. Upcoming FDA decisions for pediatric Afrezza and the Furoscix ReadyFlow Autoinjector are key catalysts, while the investment narrative now places greater emphasis on its platform's broader revenue potential beyond a narrow product focus.
MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline
MannKind Corp (MNKD) is a biopharmaceutical company focused on inhaled therapeutics, with Afrezza inhaled insulin as its flagship product. The article discusses the company's business model, revenue drivers such as Afrezza sales and collaborations, and its competitive position in the diabetes and respiratory therapy markets. It also highlights risks and catalysts for investors, emphasizing the importance of Afrezza's commercial trajectory and successful pipeline execution.
FY2026 EPS Estimates for MannKind Increased by HC Wainwright
HC Wainwright has increased its FY2026 EPS estimate for MannKind to ($0.18) from ($0.19), reaffirming a "Buy" rating and a $10 price target despite the company missing Q1 EPS and revenue expectations. MannKind reported Q1 EPS of ($0.05) and revenue of $90.17 million, which was below consensus but represented a 15.1% year-over-year increase. The stock holds a "Moderate Buy" consensus rating with an average target price of $8.84 from multiple analysts.
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M
MannKind Corp. (NASDAQ: MNKD) reported total revenues of $90.2 million for Q1 2026, marking a 15% increase year-over-year, driven by Furoscix net sales and Tyvaso DPI royalties. The company is preparing for key FDA action dates for Afrezza and Furoscix, while also advancing its development pipeline with trials for Nintedanib DPI and continued collaboration for Ralinepag DPI. Despite increased operating costs due to acquisitions and commercial launch preparations, MannKind continues to focus on innovative inhaled therapeutic products.
MannKind Corp stock (US5638651064): respiratory drug specialist in focus after latest quarterly upda
MannKind Corp has released its latest quarterly figures, providing updates on its inhaled therapies pipeline and commercialization strategy. The company focuses on inhaled therapeutics for chronic diseases like diabetes and pulmonary arterial hypertension, with Afrezza being its flagship product. Investors are monitoring its balance between Afrezza revenues, collaboration income, and R&D expenses as it navigates growth in the biotech sector.
MNKD (NASDAQ) amendment shows RSU resale filing via Morgan Stanley
An amendment to a Form 144 filing for MannKind Corporation (MNKD) indicates a proposed sale of Common securities related to Restricted Stock Units (RSU). The transaction dates listed are May 10, 2026, and May 12, 2026, with Morgan Stanley Smith Barney LLC identified as the broker. This filing updates previous information regarding security details for an RSU resale.
MannKind Corp stock (US5638651064): Biopharma innovator in inhaled therapies
MannKind Corporation (MNKD) is a biopharmaceutical company focused on inhaled therapies, notably its Afrezza inhaled insulin for diabetes. The company's Technosphere platform allows for rapid absorption of medications through the lungs, and it continues to expand its pipeline for other conditions. With a focus on the US market, MannKind aims to capitalize on the growing demand for patient-friendly drug delivery systems and is appealing to investors seeking exposure to the diabetes care sector.
MannKind EVP David Thomson sells $9,978 in company stock
David Thomson, EVP, General Counsel & Secretary at MannKind Corp (NASDAQ:MNKD), sold 3,033 shares for $9,978 on May 12, 2026, as part of a Rule 10b5-1 trading plan. Additionally, 12,387 shares valued at $43,602 were withheld on May 11, 2026, to cover tax obligations from vested Restricted Stock Units. Following these transactions, Thomson directly holds 826,299 shares, while recent company news includes a 15% Q1 2026 revenue increase to $90 million due to the scPharmaceuticals acquisition, despite a slight non-GAAP net loss.
Mannkind director Steven Binder sells $55,732 MNKD stock
Mannkind director Steven Binder sold 16,940 shares of MNKD stock worth $55,732 on May 12, 2026, and an additional 5,560 shares valued at $19,571 on May 11, 2026, to cover tax obligations. These transactions occurred as Mannkind shares have declined 44% year-to-date, though InvestingPro suggests the stock is undervalued. Binder now directly holds 808,008 shares.
MannKind EVP David Thomson sells $9,978 in company stock
MannKind Executive Vice President David Thomson sold 3,033 shares of company stock for $9,978 on May 12, 2026, as part of a Rule 10b5-1 trading plan. Additionally, Thomson disposed of 12,387 shares, valued at $43,602, on May 11, 2026, to cover tax obligations from vested Restricted Stock Units. Following these transactions, Thomson directly holds 826,299 shares of MannKind Corp.
MANNKIND CORP (MNKD) officer has shares withheld to cover RSU taxes
Stuart A. Tross, Chief People & Workplace Officer at MANNKIND CORP (MNKD), reported a routine tax-related share disposition where 8,073 shares of common stock were withheld to cover tax withholding obligations upon the vesting of restricted stock units. The shares were valued at $3.52 each, and after this transaction, Tross directly holds 992,224 shares. This was a non-market transaction for tax purposes, not a sale.
MannKind (MNKD) EVP trades shares under pre-set Rule 10b5-1 plan
David Thomson, EVP, General Counsel & Secretary of MannKind Corp (MNKD), reported an open-market sale of 3,033 shares at an average price of $3.29, executed under a Rule 10b5-1 trading plan. Additionally, 12,387 shares were withheld for tax obligations related to restricted stock units. Following these transactions, Thomson directly holds 826,299 shares of MannKind common stock.
Director Steven Binder trades MannKind (MNKD) shares under 10B5-1 plan
MannKind Corp director Steven B. Binder sold 16,940 shares of common stock at a weighted average price of $3.29 per share on May 12, 2026, under a pre-established Rule 10B5-1 trading plan. Additionally, 5,560 shares were withheld on May 11, 2026, for tax obligations related to vested restricted stock units. Following these transactions, Binder directly holds 808,008 MannKind shares.
Wells Fargo Raises its Price Target on MannKind (MNKD) to $10
Wells Fargo and H.C. Wainwright have both raised their price targets on MannKind Corporation (MNKD) to $10, maintaining Overweight and Buy ratings respectively. This follows new disclosures regarding ralinepag DPI involvement and upcoming PDUFA decisions for Afrezza and Furoscix, with analysts seeing multiple new avenues for revenue growth and pipeline upside. Despite Q1 results coming in below expectations, MannKind's CEO, Michael Castagna, highlighted 2026 as its most catalyst-rich year, focusing on commercial portfolio expansion and development pipeline diversification.
Wells Fargo Raises its Price Target on MannKind (MNKD) to $10
Wells Fargo and H.C. Wainwright have both raised their price targets on MannKind Corporation (MNKD) to $10 from $8, maintaining Overweight and Buy ratings respectively. The upgrades come as MannKind anticipates several catalysts in 2026, including PDUFA decisions for Afrezza and Furoscix, and expanded collaborations. Despite Q1 earnings missing consensus estimates, analysts see potential for revenue growth and pipeline upside, with a focus on royalty and collaboration revenue streams.
[144] MANNKIND CORP SEC Filing
This article reports on a Form 144 SEC filing by MANNKIND CORP (MNKD) on May 12, 2026, at 04:34 PM. The filing indicates a neutral impact and sentiment. The Form 144 is a notice of proposed sale of securities, detailing sales of Common stock by an individual through Morgan Stanley Smith Barney LLC.
10 Best Penny Stocks to Buy Before They Explode
This article identifies MannKind Corporation (NASDAQ: MNKD) as one of the best penny stocks to buy. Wells Fargo and H.C. Wainwright both raised their price targets on MNKD to $10, maintaining Overweight and Buy ratings respectively, highlighting potential revenue growth and pipeline upside despite a Q1 earnings miss. CEO Michael Castagna anticipates 2026 to be a catalyst-rich year for the biopharmaceutical company, driven by potential new approvals and expanded collaborations.
MannKind Corp stock (US5638651064): Q1 2026 earnings miss on EPS, revenue up 15%
MannKind Corp reported its Q1 2026 earnings, missing analyst EPS estimates by $0.03 with an EPS of -$0.05, while revenue increased 15.1% year-over-year to $90.17 million but also fell short of expectations. The company's primary revenue driver, Afrezza, contributed to the growth despite the missed forecasts, reflecting the ongoing expansion of its inhaled therapeutics portfolio. MannKind, a Nasdaq-listed biopharma, focuses on developing products for endocrine and other disorders, with its core business model centered on inhaled delivery innovations like Afrezza for diabetes management.
MannKind rises as collaboration with United Therapeutics expands
MannKind Corporation's shares are rising after its expanded collaboration with United Therapeutics to develop an inhalable treprostinil product for pulmonary hypertension. This long-term agreement has MannKind developing and obtaining FDA approval for the product, with United Therapeutics funding all development costs and retaining worldwide commercialization rights, reinforcing a prior collaboration for Tyvaso DPI.
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets
H.C. Wainwright and Wells Fargo have both raised their price targets for MannKind Corporation (MNKD) from $8 to $10, maintaining their Buy and Overweight ratings, respectively. H.C. Wainwright emphasized the durability and upside potential of the company’s royalty and collaboration revenue streams, while Wells Fargo highlighted upcoming PDUFA decisions for Afrezza and Furoscix, along with involvement in Ralinepag DPI, as drivers for future revenue growth.
5 Best US Stocks Under $5 to Buy
This article identifies MannKind Corporation (NASDAQ: MNKD) as one of the top US stocks under $5 to buy. It highlights recent price target increases from H.C. Wainwright and Wells Fargo, both citing the company's royalty and collaboration revenue streams, pipeline potential, and upcoming PDUFA decisions for products like Afrezza and Furoscix as reasons for their positive outlook. MannKind is a biopharmaceutical company specializing in inhaled therapeutic products for endocrine and orphan lung diseases.
MNKD Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for MannKind Corp (MNKD). It indicates an overall "Buy" technical sentiment based on a proprietary analysis of 13 technical signals, despite some sell indicators from RSI and CCI. The analysis also details support and resistance levels, moving averages, and momentum indicators like MACD and RSI.
MannKind (MNKD) CEO clarifies 100,000-share Form 4 error in amendment
MannKind CEO Michael Castagna filed an amended Form 4 to correct an error in a previous filing. The amendment clarifies that 100,000 MannKind common shares were mistakenly attributed to him, when in fact they were acquired by his spouse in a segregated retirement account in which he has no pecuniary interest. As a result, Castagna was not obligated to file the original Form 4 for this transaction, and it should be considered revoked.
Is MannKind’s (MNKD) Profit Reversal Amid Rising Revenue Rewriting Its Investment Narrative?
MannKind Corporation reported increased revenue in Q1 2026, reaching US$90.17 million, but shifted from a net income of US$13.16 million to a net loss of US$16.62 million. This indicates a challenge in cost control and margin recovery, despite growth in sales. The article highlights the upcoming FDA decision on Afrezza’s pediatric sBLA as a key catalyst that could influence the investment narrative regarding MannKind's future profitability and funding needs.
MannKind Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:MNKD) 2026-05-07
MannKind Corporation (MNKD) published its Q1 2026 earnings call presentation, revealing an EPS of -$0.02, missing estimates by $0.03, and revenue of $90.17M, missing by $15.14M despite a 15.08% year-over-year increase. The presentation is available for investors to review details regarding the company's financial performance.
MannKind (NASDAQ:MNKD) Price Target Raised to $4.75
Royal Bank of Canada raised its price target for MannKind (NASDAQ:MNKD) to $4.75, while other analysts maintain a "Moderate Buy" consensus. The company missed Q1 earnings and revenue expectations but announced a significant collaboration with United Therapeutics for a dry-powder inhalation version of ralinepag, and its CEO acquired additional shares. Despite some positive developments and insider buying, the Q1 financial performance and negative ROE remain near-term concerns.
MannKind Corporation (NASDAQ:MNKD) Q1 2026 Earnings Call Transcript
MannKind Corporation reported its Q1 2026 earnings, missing EPS expectations at $-0.05 against an expected $-0.02. Despite this, the company achieved $90 million in revenue, a 15% year-over-year increase, driven by the FURO6 acquisition. MannKind highlighted several significant milestones, including the unveiling of ralinepag DPI in collaboration with United Therapeutics, advanced preparations for the Afrezza Pediatric launch, and the upcoming FURO6 ReadyFlow auto-injector approval, positioning the company for diversified long-term growth.
MNKD Stock Records Biggest Single-Day Gains In Over 5 Years, Breaches A Key Technical Milestone – What’s Driving This Rally?
MannKind Corp. (MNKD) shares surged over 30% after the company highlighted progress on an inhaled therapy for pulmonary arterial hypertension, developed in partnership with United Therapeutics (UTHR). The drug, Ralinepag DPI, aims for convenient once-daily dosing. MannKind could receive up to $35 million in milestone payments and royalties, while retail sentiment on Stocktwits turned bullish.
MannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPS
MannKind (NASDAQ:MNKD) reported its quarterly earnings, missing analysts' consensus estimates by $0.03 EPS with a GAAP net loss of $16.6M. Despite the mixed financial results, the company's shares rose by approximately 24.5% due to an expanded collaboration with United Therapeutics, strong FUROSCIX sales momentum, and upcoming PDUFA dates for Afrezza Pediatrics and FUROSCIX ReadyFlow. Analysts hold a "Moderate Buy" rating with an average target price of $8.69, and recent insider buying activity was noted.
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation announced its first-quarter 2026 financial results, reporting total revenues of $90.2 million, a 15% increase year-over-year. The company highlighted significant progress in its corporate transformation strategy, with multiple product updates including upcoming PDUFA dates for Afrezza’s pediatric indication and the Furoscix ReadyFlow Autoinjector, and advancement of its pipeline programs. MannKind's CEO, Michael Castagna, emphasized 2026 as a "catalyst-rich year" with potential approvals and portfolio expansion aimed at delivering long-term shareholder value.
MannKind (NASDAQ: MNKD) Q1 2026 revenue rises 15% as Furoscix ramps
MannKind Corporation reported a 15% increase in total revenues for Q1 2026, reaching $90.2 million, primarily driven by strong Furoscix sales and higher royalties from Tyvaso DPI. Despite this growth, the company recorded a net loss of $16.6 million due to significant increases in operating expenses, including cost of goods sold, R&D, and SG&A. MannKind also highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, along with progress in its development pipeline.
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported a 15% increase in total revenues for Q1 2026, reaching $90.2 million, driven by growth in Furoscix sales and royalties. The company highlighted significant upcoming milestones including PDUFA dates for Afrezza pediatric indication and Furoscix ReadyFlow Autoinjector, alongside advancing its pipeline with Nintedanib DPI entering Phase 2 and an expanded collaboration for Ralinepag DPI. MannKind aims to diversify its commercial portfolio and development pipeline to deliver long-term shareholder value.
MannKind: Q1 Earnings Snapshot
MannKind Corp. reported a first-quarter loss of $16.6 million, or 5 cents per share, which missed Wall Street's expectations of a 2 cents per share loss. The biopharmaceutical company also reported revenue of $90.2 million, falling short of analyst estimates of $103.7 million.
MNKD Stock Pops As Traders Bet On Catalyst Wave
MannKind Corporation (MNKD) stock saw a significant jump of over 41% as traders anticipate upcoming catalysts, including FDA PDUFA dates and clinical readouts. Despite recent price target cuts from Truist and Mizuho, both firms maintained positive ratings, indicating continued confidence in the company's long-term prospects. The Q1 2026 earnings release and business update on May 6, 2026, is a key event traders are watching for further momentum.
MannKind advances inhaled ralinepag program for lung diseases
MannKind Corporation announced it is advancing its dry powder inhalation (DPI) formulation of ralinepag (MNKD-1501) for pulmonary hypertension and fibrotic lung diseases, in collaboration with United Therapeutics. United Therapeutics made an additional $5 million payment to MannKind and will lead development, regulatory, and commercialization, with MannKind eligible for up to $35 million in milestones and 10% royalties. This initiative builds on the success of Tyvaso DPI and aims to broaden treatment options for these conditions, following positive phase 3 results for oral ralinepag.
MannKind Announces Ralinepag Dry Powder Inhalation (DPI)
MannKind Corporation announced it is developing a dry powder inhalation (DPI) formulation of ralinepag (MNKD-1501) for United Therapeutics, supported by an additional $5 million payment. This formulation is intended for pulmonary hypertension (PAH) and fibrotic lung diseases, building on the success of oral ralinepag in a pivotal Phase 3 study. MannKind is eligible for up to $35 million in development milestones and 10% royalties on net sales.
Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?
MannKind Corporation (NASDAQ: MNKD) is presented as a fundamentally strong penny stock, despite Truist trimming its price target to $6 from $7 while reiterating a Buy rating. The company boasts a 45.80% year-over-year quarterly revenue growth and an upside potential of nearly 165%, supported by a strong pipeline of catalysts including PDUFA dates for Afrezza and Furoscix ReadyFlow, and updates for MNKD-201.
MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday
MannKind (NASDAQ:MNKD) is expected to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts forecasting earnings of ($0.02) per share and revenue of $105.38 million. The biopharmaceutical company recently missed EPS expectations in the prior quarter but reported strong revenue growth of 45.8% year-over-year. The stock holds an average analyst rating of "Moderate Buy" with an $8.69 average price target, driven partly by recent insider buying and institutional interest.
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The biopharmaceutical company will also host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, with a replay available on their investor relations website.
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation announced it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, accessible via its investor relations website. MannKind specializes in developing solutions for cardiometabolic and orphan lung diseases.
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation (Nasdaq: MNKD) announced it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, accessible via its investor relations website.
